Lesinurad

Randomized, double-blind, multicenter, placebo-controlled, dose titration, safety and pharmacodynamics pilot study of RDEA594 versus placebo and open-label allopurinol in hyperuricemic subjects with symptomatic gout

An open label, non-randomised crossover study to assess the prototype extended release formulations of RDEA594 and the effect of food on the bioavailability of those extended release formulations

A phase 1b study to evaluate the potential pharmacokinetic and pharmacodynamic interaction between RDEA594 and febuxostat in gout patients with hyperuricemia

A double-blind randomized crossover trial to define the ECG effects of lesinurad using the highest therapeutic and a supratherapeutic dose of lesinurad compared to placebo and moxifloxacin (a positive control) in healthy men and women: a thorough QT study

Randomized, double-blind, multicenter, placebo-controlled, safety and efficacy study of RDEA594 versus placebo in the treatment of hyperuricemia in patients with gout